TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Safety and Effectiveness of Sculptra Aesthetic for Correction of Cheek Wrinkles

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Intent to undergo correction of cheek wrinkles on both sides of the face and a Galderma Cheek Wrinkles Scale (GCWS) At Rest score of Moderate or Severe on EACH side of the face.~Exclusion Criteria:~* Known/previous allergy or hypersensitivity to any of the Sculptra Aesthetic constituents.~* Previous tissue augmenting therapy, contouring or revitalization treatment in the face, except the lips, with any of the following fillers prior to Baseline visit:~  1. Collagen, Hyaluronic Acid - 12 months~ 2. Calcium Hydroxyapatite (CaHa), Poly L- Lactic Acid (PLLA) or permanent (nonbiodegradable)- Prohibited

- Gender: ALL
- Minimum Age: 21 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Control Group: No-treatment (Type: NO_INTERVENTION): Participants will receive no treatment during the study.
- Treatment Group: Sculptra Aesthetic (Type: EXPERIMENTAL): Participants will be injected with Sculptra Aesthetic by Treating Investigator at Day 1 until optimal correction achieved (up to 4 total treatment sessions)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study Based on Data From German Registries That Looks at Characteristics of People Who Take the Medicine Empagliflozin for Type 2 Diabetes

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: RETROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* At least two outpatient T2DM diagnoses (ICD E11.-) in two different quarters and/or at least one inpatient T2DM diagnosis (ICD E11)~* At least one prescription of an empagliflozin-containing antidiabetic drug: Jardiance® (Empagliflozin, ATC A10BK03, former A10BX12) or Synjardy® (Empagliflozin/ Met¬for¬min, ATC A10BD20)~Exclusion Criteria:~* Any diagnosis of T1DM

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Patients receiving Empagliflozin until mid Sep 2015 (Type: None): Patients receiving Empagliflozin before the EMPA-REG-OUTCOME study was published time until mid-Sept. 2015; Cohort 1
- Patients receiving Empagliflozin until CV Label Change time (Type: None): Patients receiving Empagliflozin starting from the EMPA-REG-OUTCOME study being published until CV Label Change time from mid-Sept. 2015-mid-Jan. 2017; Cohort 2
- Patients receiving Empagliflozin until last available data cut (Type: None): Patients receiving Empagliflozin starting from mid-Jan. 2017 until last; Cohort 3

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy Study of the Use of Sequential DFP-DFO Versus DFP

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Thalassemia major patients with serum ferritin concentration between 800 to 3,000 ng/ml and were over 13 years of age~Exclusion Criteria:~* Known intolerance to one of the trial treatments~* Platelet count \< 100,000/mm3 or or leukocyte count \< 3,000/mm3~* Severe liver damage indicated by ascites~* Heart failure

- Gender: ALL
- Minimum Age: 13 Years
- Maximum Age: 60 Years
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): Sequential treatment including DFP at 75 mg/kg, divided into three oral daily doses, for four days per week and DFO by subcutaneous infusions (8-12h) at 50 mg/kg/day for the remaining three days per week
- 2 (Type: ACTIVE_COMPARATOR): Deferiprone alone at 75 mg/kg divided into three oral daily doses

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Effect of IV Iron Isomaltoside on Postoperative Anemia in Total Knee Arthroplasty Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: DOUBLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Adult patients undergoing total knee arthroplasty~Exclusion Criteria:~* bilateral total knee arthroplasty~* hematochromatosis or hemosiderosis~* hemolytic anemia~* history of drug allergy~* liver cirrhosis or hepatitis~* systematic lupus erythematosus~* rheumatic arthritis~* allergic disease~* history of transfusion within one month from surgery~* parturient

- Gender: ALL
- Minimum Age: 19 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Treatment (Type: EXPERIMENTAL): Patients in this group would receive Iron Isomaltoside 1000 (Monofer®) after main procedure of total knee arthroplasty. The dose of iron isomaltoside would be determined based on the patient's body weight.
- Control (Type: NO_INTERVENTION): Patients in this group would receive 100ml of normal saline after main procedure of total knee arthroplasty.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Changing the Healthcare Delivery Model

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: HEALTH_SERVICES_RESEARCH
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Age 21 to 75 years old~* Medicaid insurance coverage, Medicare insurance coverage or Affordable Health Care Act insurance coverage~* Fluent in English or Spanish and able to read a text message~* Diagnosed with diabetes mellitus type 2 and A1C is \> 8%~Acceptable values will be either :~* A1c obtained within one month prior to baseline (as long as there were no diabetes changes made during that month) or~* A new A1c measured at the baseline screening visit.~* Meets \< 10 of the wellness behaviors and clinical goals if diagnosed with hypertension Meets \< 9 of the wellness behaviors and clinical goals if not diagnosed with hypertension~Exclusion Criteria:~* Stage 5 chronic kidney disease or end stage renal disease on dialysis~* Terminal illness (expected survival of less than one year)~* Severe dementia or uncontrolled mental illness~* Gestational diabetes mellitus~* Use of an insulin pump~* Inability to use a cellular phone~* Unable to use software application on cellular phone~* Pregnant or planning to get pregnant

- Gender: ALL
- Minimum Age: 21 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Mobile health care application (Type: ACTIVE_COMPARATOR): Patients will be assisted with managing their health by a cell phone application used to promote self care for patients with diabetes.
- Community Health Worker (CHW) (Type: ACTIVE_COMPARATOR): CHWs assist study patients in managing there health care in various ways.
- CHWs and mobile health care application (Type: EXPERIMENTAL): Patients will receive assistance in managing their health from both CHWs and the mobile health cell phone application

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: The EFFect of hIgh Dose ClopIdogrel treatmENT in Patients With Clopidogrel Resistance

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* The patients; who have planned elective PCI and have had written informed consent for participation to study.~* Age\>18 year-old,~* The native coronary artery;lesion with narrowing \>=70%~Exclusion Criteria:~* Patients have allergy for ASA, Clopidogrel and heparin~* Patients who performed primary PCI~* Patients with acute coronary syndrome~* Patients with have a history of PCI and use clopidogrel~* Patients on warfarin therapy~* Patients who have bleeding diathesis, or have high risk for bleeding.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- high dose clopidogrel (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: The MiDAS ENCORE Study

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. 65 years or older and a Medicare beneficiary.~2. Patients experiencing neurogenic claudication symptoms for at least 3 months duration which has failed to respond or poorly responded to physical therapy, home exercise programs, and oral analgesics.~3. LSS with neurogenic claudication diagnosed via:~   1. Symptomatic diagnosis and~  2. Radiologic evidence of LSS with unilateral or bilateral ligamentum flavum \>2.5mm confirmed by pre-op MRI or CT performed within 12 months of baseline visit.~4. Patients with comorbid conditions commonly associated with spinal stenosis, such as osteophytes, facet hypertrophy, minor spondylolisthesis, foraminal stenosis, and/or disk protrusion may be included unless the treating physician has determined that the condition is too advanced.~5. Available to complete 6 month and one year follow-up visits.~Exclusion Criteria:~1. ODI Score \< 31 (0-100 ODI Scale).~2. NPRS Score \< 5 (0-10 NPRS Scale).~3. Prior surgery at any treatment level.~4. History of recent spinal fractures with current related pain symptoms.~5. Patients with Grade III or higher spondylolisthesis.~6. Motor deficit or disabling back and/or leg pain from causes other than LSS neurogenic claudication (e.g., acute compression fracture, metabolic neuropathy, or vascular claudication symptoms, etc.).~7. Unable to walk ≥ 10 feet unaided before being limited by pain. In this context, 'unaided' means without the use of a cane, walker, railing, wall, another person or any other means of walking assistance.~8. Patients previously randomized and/or treated in this clinical study.~9. Patients that have previously received the MILD procedure.~10. ESI during eight weeks prior to study enrollment.~11. Epidural lipomatosis (if it is deemed to be a significant contributor of canal narrowing by the physician).~12. On (or pending) Workman's Compensation or known to be considering litigation associated with back pain.

- Gender: ALL
- Minimum Age: 65 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- MILD (Type: ACTIVE_COMPARATOR): The MILD procedure is an image-guided minimally-invasive lumbar decompression
- Epidural Steroid Injection (ESI) (Type: ACTIVE_COMPARATOR): An epidural steroid injection (ESI) is a combination of a corticosteroid with a local anesthetic pain relief medicine.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: VIVO Clinical Study

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* symptomatic venous outflow obstruction in one iliofemoral venous segment (i.e., one limb) per patient, demonstrated by:~  * CEAP C ≥ 3, or~ * VCSS pain score ≥ 2~Key Exclusion Criteria:~* \< 18 years of age;~* pregnant or planning to become pregnant in the next 12 months;~* planned surgical or interventional procedures of the target limb (except thrombolysis and/or thrombectomy in preparation for the procedure or vena cava filter placement prior to stent implantation in patients at high risk for pulmonary embolism) within 30 days prior to or any time after the study procedure;~* planned surgical or interventional procedures for other medical conditions (i.e., not associated with the target limb) within 30 days prior to or after the study procedure;~* lesions with intended treatment lengths extending into the inferior vena cava or below the level of the lesser trochanter;~* lesion with malignant obstruction;~* previous stenting of the target vessel;~* iliofemoral venous segment unsuitable for treatment with available sizes of study devices.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Zilver Vena Venous Self-Expanding Stent (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Sugammadex and Neostigmine at Residual Neuromuscular Blockade

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: None
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Patients ASA physical status I - III~* Patients over 18 years~* Patients scheduled for general anesthesia with intubation using rocuronium~* Patients having given informed consent to the study~Exclusion Criteria:~* Anatomic and functional malformations with expected difficult intubation~* Known or suspected neuromuscular disease~* Significant hepatic or renal dysfunction~* Known or suspected history or family history of disposition to malignant hyperthermia~* Known or suspected allergy towards sugammadex, anesthetics, muscle relaxants, or other drugs used for general anesthesia~* Use of drugs that interfere with muscle relaxants~* Patients, included in another trial within the last 30 days~* Patients, with legal guidant~* Patients with contraindication towards the use of Sugammadex, neostigmine or glycopyrrolate~* Patients, which have already participated in a sugammadex trial~* Pregnant women (exclusion of pregnancy: postmenopausal status, negative β- HCG screen, status post tubal ligation)~* Breastfeeding women

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Sgx 0.25 (Type: None): Sugammadex group: Different doses of sugammadex for reversal of shallow neuromuscular blockade
- Sgx 0.5 (Type: None): Sugammadex group: Different doses of sugammadex for reversal of shallow neuromuscular blockade
- Sgx 0.75 (Type: None): Sugammadex group: Different doses of sugammadex for reversal of shallow neuromuscular blockade
- Sgx 1.0 (Type: None): Sugammadex group: Different doses of sugammadex for reversal of shallow neuromuscular blockade
- Sgx 1.25 (Type: None): Sugammadex group: Different doses of sugammadex for reversal of shallow neuromuscular blockade
- Neo 10 (Type: None): Neostigmine group: Different doses of neostigmine for reversal of shallow neuromuscular blockade
- Neo 25 (Type: None): Neostigmine group: Different doses of neostigmine for reversal of shallow neuromuscular blockade
- Neo 40 (Type: None): Neostigmine group: Different doses of neostigmine for reversal of shallow neuromuscular blockade
- Neo 55 (Type: None): Neostigmine group: Different doses of neostigmine for reversal of shallow neuromuscular blockade
- Neo 70 (Type: None): Neostigmine group: Different doses of neostigmine for reversal of shallow neuromuscular blockade
- Saline (Type: None): Saline group: Saline as placebo

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study of First Line Treatment With Avastin (Bevacizumab) in Combination With Carboplatin and Weekly Paclitaxel in Patients With Ovarian Cancer

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria~* Female patients, ≥ 18 years of age.~* Epithelial ovarian, fallopian tube, or primary peritoneal cancer.~* Initial surgery, but no chemotherapy or radiotherapy.~* Eastern Cooperative Oncology Group (ECOG) performance status of 0-2.~Exclusion Criteria~* Non-epithelial tumors.~* Ovarian tumors with low malignant potential.~* Previous systemic anti-cancer therapy for ovarian cancer.~* History or evidence of synchronous primary endometrial cancer.~* Current or recent daily treatment with aspirin (\> 325mg/day) or with full dose anticoagulant or thrombolytic agents for therapeutic purposes.

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Bevacizumab + paclitaxel + carboplatin (Type: EXPERIMENTAL): Participants received 6-8 (at the investigator's discretion) 3-week cycles of bevacizumab 7.5 mg/kg intravenously (iv) on Day 1 of each cycle, paclitaxel 80 mg/m\^2 iv on Days 1, 8, and 15 of each cycle, and carboplatin iv to an area under the curve of 6 on Day 1 of each cycle. The initial dose of carboplatin was calculated according to the Calvert formula (mg = \[glomerular filtration rate + 25\] x 6). Following the combination treatments, participants received up to 17 3-week cycles of bevacizumab 7.5 mg/g iv alone.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Medical Research Study to Evaluate the Effects of ACT-246475 in Adults With Coronary Artery Disease

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Main Inclusion Criteria:~1. Signed informed consent prior to any study-mandated procedure.~2. Male and female subjects aged from 18-85 years, inclusive.~3. For women of childbearing potential: Negative urine pregnancy test at Visit 1 and at Visit 2 before randomization.~4. Stable Coronary artery disease (CAD) defined by the presence of any of the following conditions:~   1. History of CAD with coronary artery stenosis on coronary angiogram ≥50%.~  2. Previously documented myocardial infarction occurring more than 3 months prior to randomization.~5. Antiplatelet background therapy stable for at least 1 month prior to randomization.~6. Body weight ≥ 40.0 kg (88.2 lbs).~Main Exclusion Criteria:~1. Acute coronary syndrome, percutaneous coronary intervention or any intervention for peripheral artery disease within 3 months prior to randomization.~2. Acute ischemic stroke or transient ischemic attack (TIA) within 3 months prior to randomization.~3. Active internal bleeding, or medical history of recent (\< 1 month) bleeding disorders or conditions associated with high risk of bleeding (e.g., clotting disturbances, gastrointestinal bleed, hemoptysis).~4. Hemoglobin ≤ 10 g/dL at screening.~5. Loss of at least 250 mL of blood within 3 months of screening.~6. Use of anticoagulants (oral, parenteral) or fibrinolytic therapy within 24 h prior to screening (Visit 1).~7. Known platelet disorders (e.g., thrombasthenia, thrombocytopenia, von Willebrand disease).~8. Pregnant or breastfeeding women.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 85 Years
- Healthy Volunteers: f

Study Arms:
- Selatogrel 8 mg (Type: EXPERIMENTAL): Selatogrel (ACT-246475) is given as a single subcutaneous dose of 8 mg administered in a volume of 0.8 mL. Administration will be performed at the investigational site by qualified personnel.
- Selatogrel 16 mg (Type: EXPERIMENTAL): Selatogrel (ACT-246475) is given as a single subcutaneous dose of 16 mg administered in a volume of 0.8 mL. Administration will be performed at the investigational site by qualified personnel.
- Placebo (Type: PLACEBO_COMPARATOR): Placebo matching ACT-246475 is supplied in sealed glass vials for reconstitution with water for injection. Placebo will be given as a single subcutaneous dose matching selatogrel to be administered in a volume of 0.8 mL. Administration will performed at the investigational site by qualified personnel.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Multicenter Extension Study of Velaglucerase Alfa in Japanese Patients With Gaucher Disease

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* The patient has completed treatment with EOW velaglucerase alfa through Week 51 of study HGT-GCB-087.~* Female patients of child bearing potential must agree to use a medically acceptable method of contraception at all times during the study.~* The patient, the patient's parent(s)or legal guardian(s) has provided written informed consent that has been approved by the Institutional Review Board/Independent Ethics Committee(IRB/IEC)~* The patient must be sufficiently cooperative to participate in this clinical study as judged by the Investigator.~Exclusion Criteria:~* The patient has received treatment with any investigational drug, other than velaglucerase alfa, or investigational device within 30 days prior to study entry; such use during the study is not permitted.~* The patient, patient's parent(s), or patient's legal guardian(s) is/are unable to understand the nature, scope, and possible consequences of the study.~* The patient has a significant comorbidity, as determined by the Investigator that might affect study data or confound the study results.~* The patient is unable to comply with the protocol as determined by the Investigator.

- Gender: ALL
- Minimum Age: 2 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- velaglucerase alfa (Type: EXPERIMENTAL): 15 to 60 U/kg, EOW via intravenous infusion

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete